Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Asalyxa Bio, a US-based developer of immune cell-targeted therapeutics spun out of University of Michigan, has completed a $2m seed round co-led by Research Bridge Partners and ID Ventures, with participation from the Biosciences Research and Commercialization Center at Western Michigan University, Michigan Rise Pre-Seed Fund III, Ann Arbor Spark, Woodward Angels and undisclosed investors. The round will allow Asalyxa to move its lead asset into the clinic.
…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
